Smolen, J. S., Boers, M., Abadie, E. C., Breedveld, F. C., Emery, P., Bardin, T., … Task Force of the Group for the Respect of Ethics and Excellence in Science, . (2011). Updating the 2003 European regulatory requirements for registering disease-modifying drugs to be used in the treatment of rheumatoid arthritis. Rheumatology (Oxford), 50(10), 1732–1736. https://doi.org/10.1093/rheumatology/keq413

Smolen, Josef S., Maarten Boers, Eric C. Abadie, Ferdinand C. Breedveld, Paul Emery, Thomas Bardin, Niti Goel, et al. “Updating the 2003 European regulatory requirements for registering disease-modifying drugs to be used in the treatment of rheumatoid arthritis.” Rheumatology (Oxford) 50, no. 10 (October 2011): 1732–36. https://doi.org/10.1093/rheumatology/keq413.

Smolen JS, Boers M, Abadie EC, Breedveld FC, Emery P, Bardin T, et al. Updating the 2003 European regulatory requirements for registering disease-modifying drugs to be used in the treatment of rheumatoid arthritis. Rheumatology (Oxford). 2011 Oct;50(10):1732–6.

Smolen, Josef S., et al. “Updating the 2003 European regulatory requirements for registering disease-modifying drugs to be used in the treatment of rheumatoid arthritis.” Rheumatology (Oxford), vol. 50, no. 10, Oct. 2011, pp. 1732–36. Pubmed, doi:10.1093/rheumatology/keq413.

Smolen JS, Boers M, Abadie EC, Breedveld FC, Emery P, Bardin T, Goel N, Ethgen DJ, Avouac BP, Durez P, Flamion B, Laslop A, Miossec P, Reiter S, Reginster J-Y, Task Force of the Group for the Respect of Ethics and Excellence in Science. Updating the 2003 European regulatory requirements for registering disease-modifying drugs to be used in the treatment of rheumatoid arthritis. Rheumatology (Oxford). 2011 Oct;50(10):1732–1736.